1. CMU Intellectual Repository
  2. Academic Support Units
  3. Chiang Mai University Library
  4. CMUL: Journal Articles
Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/62978
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTim R. Cresseyen_US
dc.contributor.authorLinda Harrisonen_US
dc.contributor.authorJullapong Achalapongen_US
dc.contributor.authorPrateep Kanjanavikaien_US
dc.contributor.authorOrada Patamasingh Na Ayudhayaen_US
dc.contributor.authorPrateung Liampongsabuddhien_US
dc.contributor.authorThitiporn Siriwachirachaien_US
dc.contributor.authorChaiwat Putiyanunen_US
dc.contributor.authorPornnapa Suriyachaien_US
dc.contributor.authorCamlin Tierneyen_US
dc.contributor.authorNicolas Salvadorien_US
dc.contributor.authorDujrudee Chinwongen_US
dc.contributor.authorLuc Deckeren_US
dc.contributor.authorYardpiroon Tawonen_US
dc.contributor.authorTrudy V. Murphyen_US
dc.contributor.authorNicole Ngo-Giang-Huongen_US
dc.contributor.authorGeorge K. Siberryen_US
dc.contributor.authorGonzague Jourdainen_US
dc.date.accessioned2018-12-14T04:03:46Z-
dc.date.available2018-12-14T04:03:46Z-
dc.date.issued2018-12-01en_US
dc.identifier.issn10986596en_US
dc.identifier.other2-s2.0-85057201918en_US
dc.identifier.other10.1128/AAC.01686-18en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85057201918&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/62978-
dc.description.abstractCopyright © 2018 American Society for Microbiology. We assessed tenofovir exposure during pregnancy and postpartum in hepatitis B virus (HBV)-infected HIV-uninfected women receiving tenofovir disoproxil fumarate (TDF) to prevent mother-to-child transmission of HBV. Data from 154 women who received TDF within a randomized controlled trial were included. Individual plasma tenofovir exposures (area under the concentration-time curve from 0 to 24 h [AUC0-24]) were estimated using a population pharmacokinetic approach. The estimated geometric mean tenofovir AUC0-24 was 20% (95% confidence interval [95% CI], 19 to 21%) lower during pregnancy than during postpartum; this modest reduction in the absence of HBV transmission suggests that no dose adjustment is needed.en_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleTenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virusen_US
dc.typeJournalen_US
article.title.sourcetitleAntimicrobial agents and chemotherapyen_US
article.volume62en_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsHarvard School of Public Healthen_US
article.stream.affiliationsUniversity of Liverpoolen_US
article.stream.affiliationsCenter for Biostatistics in AIDS Researchen_US
article.stream.affiliationsChiangrai Prachanukroh Hospitalen_US
article.stream.affiliationsBanglamung Hospitalen_US
article.stream.affiliationsNopparat Rajathanee Hospitalen_US
article.stream.affiliationsLampang Hospitalen_US
article.stream.affiliationsKhon Kaen Regional Hospitalen_US
article.stream.affiliationsChiang Kham Hospitalen_US
article.stream.affiliationsPhayao Provincial Hospitalen_US
article.stream.affiliationsInstitute of research for development, Thailanden_US
article.stream.affiliationsCenters for Disease Control and Preventionen_US
article.stream.affiliationsNational Institute of Child Health and Human Developmenten_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.
Show simple item record


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.